Is the business good?
How good a business is ARWR?
Arrowhead Pharmaceuticals, Inc. keeps −34% of every revenue dollar as operating profit, against −72% for the median Biotechnology name.
−34%
Operating margin · Biotechnology median −72% · 12 months to Q3 2026
- Share count, year on year
- +3.1%
Share count, year on year · shareholders own a smaller slice than a year ago
- R&D as % of revenue
- 108%
R&D as % of revenue
| Year | Operating margin |
|---|---|
| FY2020 | −106% |
| FY2021 | −108% |
| FY2022 | −73% |
| FY2023 | −85% |
| FY2024 | −16927% |
| FY2025 | 12% |
Details›
- Operating margin12 months to Q3 2026
- −34%
- Net margin12 months to Q3 2026
- −48%
- Free cash flow margin
- −11%
- R&D as % of revenue
- 108%
- Revenue, trailing twelve months
- $669M
- Free cash flow, trailing twelve months
- −$75M
- Net income, trailing twelve months
- −$320M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion from the cash flow statement.